
Myriad Genetics (MYGN) Stock Forecast & Price Target
Myriad Genetics (MYGN) Analyst Ratings
Bulls say
Myriad Genetics is facing challenges in its reproductive health segment, including volume declines and market share loss to competitors, as well as price compression in its hereditary cancer segment. The company's prenatal revenue declined 16% in 2Q26 and management cited ongoing volume challenges as a primary factor. However, the company is looking towards a material growth acceleration in the second half of 2026, driven by strong trends in its hereditary cancer segment and new product launches. Ultimately, the factors that are material to Myriad Genetics's success may change over time, and risks to the upside may include incremental reimbursement and market adoption of existing and new products.
Bears say
Myriad Genetics is facing significant risks to achieving their financial targets due to potential divestitures or asset sales, slower than expected volume recovery in prenatal testing, and ongoing challenges with payer denial and collection issues. Additionally, the company's low valuation does not guarantee a takeout floor and potential buyers may wait for further revenue decreases or margin deterioration before committing capital, putting further pressure on the company's financial performance. These risks are compounded by a changing segment reporting structure and potential challenges with market acceptance of Myriad's new products, such as Precise MRD and GeneSight. Finally, the Medical and Life Science Tools sector as a whole may face challenges such as reduced funding and purchasing from healthcare customers, increased regulatory hurdles, and general economic challenges.
This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.
Myriad Genetics (MYGN) Analyst Forecast & Price Prediction
Start investing in Myriad Genetics (MYGN)
Order type
Buy in
Order amount
Est. shares
0 shares